Analysis of new drugs reaching their first markets in 2010 reveals some real breakthroughs in pharmaceutical science. But they were outnumbered by me-toos and incremental innovations, writes Alex Shim
Given its late-stage pharma failures, Merck's vaccine pipeline is now the star of the company. But is its big-risk strategy a thing of the past? When Merck & Co. Inc. moved in 1992 into its gleamin